Please ensure Javascript is enabled for purposes of website accessibility

A New Cure for Painkiller Constipation

By Dave Williamson - Apr 23, 2013 at 6:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The first oral medication for opioid related constipation receives FDA approval.

Shares of Sucampo Pharmaceuticals soared 24% as the company received an expanded indication for Amitiza, which is now the only FDA-approved oral medication for constipation from taking opioid painkillers for non-cancer pain. 

In this video, health-care analyst David Williamson explains what this means for Sucampo and why, despite the size of the market, investors may not want to rush in and grab shares after today's big pop.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cubist Pharmaceuticals LLC Stock Quote
Cubist Pharmaceuticals LLC

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.